Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

ABSTRACT:

Background

Biomarker-guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not available are not eligible. Technological advancements in sequencing have made cell-free circulating DNA (cfDNA) next-generation sequencing (NGS) readily available in the clinic. The objective of the current study was to determine whether the genomic profile of mUC detected by NGS of cfDNA is similar to historical tumor tissue NGS studies. A secondary objective was to determine whether the frequency of genomic alterations (GAs) differed between lower tract mUC (mLTUC) and upper tract mUC (mUTUC).

Methods

Patients from 13 academic medical centers in the United States who had a diagnosis of mUC between 2014 and 201

SUBMITTER: Agarwal N 

PROVIDER: S-EPMC6857169 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature